<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142922">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01901484</url>
  </required_header>
  <id_info>
    <org_study_id>2012162</org_study_id>
    <nct_id>NCT01901484</nct_id>
  </id_info>
  <brief_title>Schistosoma Mansoni Morbidity in Children Aged 1-5 Years</brief_title>
  <official_title>Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <authority>Uganda: National Council for Science and Technology</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is about intestinal schistosomiasis, commonly known as bilharzia, in children
      aged 1-5 years along Lake Victoria shoreline.The children will be screened for S. mansoni
      and the effects of the disease will be assessed.Children found positive with S. mansoni will
      be treated with praziquantel and followed up for a year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has three phases: in the first phase (Phase I) a baseline pretreatment
      schistosomiasis morbidity assessment of children aged 1-5 years will take place. The
      Kato-Katz technique will be used to detect and enumerate S. mansoni eggs in faecal samples
      from each participating child.  Communities with the highest S. mansoni prevalence and
      intensity will be chosen and included in the study. In the second phase (Phase II) the S.
      mansoni positive children will be divided randomly into two intervention groups, single and
      double dose praziquantel treatment arms. Abdominal ultrasound will be combined with clinical
      examination to accurately identify hepatosplenomegaly. The sizes of both the liver and
      spleen will be examined. Anthropometric measurements and Hb for each child will also be
      recorded. In the last phase (Phase III), the effect of praziquantel on S. mansoni morbidity
      will be evaluated in all the treated children aged 1-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Presence/absence of organomegaly at Day 0 and 8 months follow-up visits</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate at 30 days after treatment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Intestinal Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Drug: Praziquantel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Praziquantel 40mg/Kg - single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Praziquantel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel</intervention_name>
    <description>All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.</description>
    <arm_group_label>Drug: Praziquantel</arm_group_label>
    <arm_group_label>Praziquantel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1-5 years

        Exclusion Criteria:

        &lt;1-5&gt; years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Nalugwa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHDC-Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annette Olsen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edridah Muheki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ministry of Health, Vector Control Division</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Nuwaha, PhD</last_name>
    <role>Study Director</role>
    <affiliation>School of Public Health, Makerere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Child Health &amp; Development Centre, College of Health Sciences , Makerere University</name>
      <address>
        <city>Kampala</city>
        <zip>6717</zip>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>Allen Nalugwa</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Schistosoma mansoni</keyword>
  <keyword>morbidity</keyword>
  <keyword>chemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schistosomiasis</mesh_term>
    <mesh_term>Schistosomiasis mansoni</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
